Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-TNFR2 monoclonal antibody BI-1808

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against tumor necrosis factor Receptor 2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B), with potential antineoplastic activity. Upon administration, anti-TNFR2 monoclonal antibody BI-1808 targets and binds to TNFR2 on tumor-associated regulatory T cells (Tregs) in the tumor microenvironment (TME), thereby preventing TNFR2-mediated signaling. This depletes intra-tumoral Tregs, induces and expands intra-tumoral CD8+ T cells, thereby enhancing T-cell-mediated immune responses against tumor cells. TNFR2 plays a role in tumor necrosis factor signaling, tumor expansion and survival.
Code name:BI 1808
BI-1808
BI1808
Search NCI's Drug Dictionary